J Gastroen Hepatol:新药雷莫芦单抗(Ramucirumab)治疗晚期胃癌有奇效!

2017-10-25 佚名 medicalxpress

近日,发表于《胃肠病学和肝脏病学杂志》上的一项最新研究表明,雷莫芦单抗(Ramucirumab)治疗晚期胃癌安全有效。

近日,发表于《胃肠病学和肝脏病学杂志》上的一项最新研究表明,雷莫芦单抗(Ramucirumab)治疗晚期胃癌安全有效。

近年来,随着生活节奏的快速化,胃癌的人数也在不断攀升,早期胃癌多数患者几乎没有明显症状,少数人会有恶心,呕吐或是类似溃疡病的上消化道症状,因此,早期胃癌很难引起足够的重视。随着肿瘤的生长,胃功能受到影响,明显的症状开始显现,如上腹不适、进食后饱胀,随着病情进展上腹疼痛加重,食欲下降、乏力。根据肿瘤的部位不同,也有特殊的表现。但是症状的出现说明已经发展成胃癌的中晚期,晚期胃癌在治疗时的难度很大,常见的治疗方法为手术,放疗,化疗和靶向药物。

在此次研究中,来自日本爱知癌症中心医院的研究人员们进行了亚组分析和临床试验,参与此次试验的参与者均为三期转移性胃癌或胃食管交界处腺癌患者。研究人员将参与者按照年龄进行分组,其中分为45岁以下组,65岁以下组,75岁以下组,以及75岁以上组,共四组。研究人员通过不同剂量的雷莫芦单抗对患者额进行治疗,发现前三个小组的胃癌患者总体存活率都有改善,唯一例外的是75岁以上的老年人,这一小组共36名参与者,他们无生存进展,也没有看到类似的积极效果。

然而,治疗的不良事件与年龄无关。研究人员在报告中指出:“尽管存在着一些年龄限制,但是我们的研究表明,雷莫芦单抗对很大比例的晚期胃癌患者具有积极的作用。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2071936, encodeId=ba7020e19369a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Sep 12 02:09:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711229, encodeId=b8511e11229a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Dec 30 13:09:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911897, encodeId=1506191189e1f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Aug 10 23:09:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276590, encodeId=d8ab12e6590ad, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426869, encodeId=6ffb142686976, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460334, encodeId=b58814603346d, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255835, encodeId=b59b25583583, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Wed Oct 25 12:36:15 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2018-09-12 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2071936, encodeId=ba7020e19369a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Sep 12 02:09:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711229, encodeId=b8511e11229a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Dec 30 13:09:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911897, encodeId=1506191189e1f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Aug 10 23:09:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276590, encodeId=d8ab12e6590ad, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426869, encodeId=6ffb142686976, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460334, encodeId=b58814603346d, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255835, encodeId=b59b25583583, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Wed Oct 25 12:36:15 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2071936, encodeId=ba7020e19369a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Sep 12 02:09:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711229, encodeId=b8511e11229a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Dec 30 13:09:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911897, encodeId=1506191189e1f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Aug 10 23:09:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276590, encodeId=d8ab12e6590ad, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426869, encodeId=6ffb142686976, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460334, encodeId=b58814603346d, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255835, encodeId=b59b25583583, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Wed Oct 25 12:36:15 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2018-08-10 snf701207
  4. [GetPortalCommentsPageByObjectIdResponse(id=2071936, encodeId=ba7020e19369a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Sep 12 02:09:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711229, encodeId=b8511e11229a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Dec 30 13:09:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911897, encodeId=1506191189e1f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Aug 10 23:09:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276590, encodeId=d8ab12e6590ad, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426869, encodeId=6ffb142686976, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460334, encodeId=b58814603346d, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255835, encodeId=b59b25583583, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Wed Oct 25 12:36:15 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2071936, encodeId=ba7020e19369a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Sep 12 02:09:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711229, encodeId=b8511e11229a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Dec 30 13:09:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911897, encodeId=1506191189e1f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Aug 10 23:09:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276590, encodeId=d8ab12e6590ad, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426869, encodeId=6ffb142686976, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460334, encodeId=b58814603346d, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255835, encodeId=b59b25583583, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Wed Oct 25 12:36:15 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2017-10-27 gwc384
  6. [GetPortalCommentsPageByObjectIdResponse(id=2071936, encodeId=ba7020e19369a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Sep 12 02:09:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711229, encodeId=b8511e11229a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Dec 30 13:09:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911897, encodeId=1506191189e1f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Aug 10 23:09:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276590, encodeId=d8ab12e6590ad, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426869, encodeId=6ffb142686976, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460334, encodeId=b58814603346d, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255835, encodeId=b59b25583583, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Wed Oct 25 12:36:15 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2071936, encodeId=ba7020e19369a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Sep 12 02:09:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711229, encodeId=b8511e11229a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Dec 30 13:09:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911897, encodeId=1506191189e1f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Aug 10 23:09:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276590, encodeId=d8ab12e6590ad, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426869, encodeId=6ffb142686976, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460334, encodeId=b58814603346d, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Fri Oct 27 03:09:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255835, encodeId=b59b25583583, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Wed Oct 25 12:36:15 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2017-10-25 中医痴

    不错的.学习了.谢谢分享!

    0

相关资讯

起死回生!罕见病新药2期临床收获积极结果

Zynerba Pharmaceuticals今日宣布了一项2期临床试验FAB-C的积极顶线结果。该试验是评估新药ZYN002治疗脆性X综合征(FXS)儿童和青少年患者,它成功抵达了主要终点,并显示出具有临床意义的改善。ZYN002曾在治疗难治性癫痫发作和骨关节炎的临床试验中失利,但此次在FXS患者中的成功,则让这款新药在研发中起死回生,让我们看到了其顺利上市,造福患者的希望。

C&EN:癌症新药PARP抑制剂获批,完美利用癌细胞弱点,粉碎它们的基因!

癌症这一令人闻风丧胆的疾病,影响着越来越多的人们,除了传统的手术及放化疗之外,新方法不断涌出,其中最为突出的就是免疫疗法,大幅的提高了癌症患者的寿命。然而,新的癌症治疗方法虽然给癌症患者带来了一线希望,但是选择却很有局限性,对另一些人来说,新药物和新方法并不适用,因此,他们仍处于无尽的等待中。近期,一种基于“合成杀伤力”的新药概念进入了人们的视野,为广大癌症患者带来了一丝曙光。研究结果以封面故事的

J CLIN INVEST :科学家发现新药可逆转糖尿病眼病!

对于数以百万计的美国人来说,他们的世界正在溶化成一个无法辨认的模糊视野。糖尿病性视网膜病是一种眼病,影响了3000万(与糖尿病斗争的三分之一人)美国人。随着患者的视力逐渐消失,它永远不会恢复,很少有治疗方法。

Oncotarget:新型抗癌药获批,成功击败引发癌症的重要基因!

阻止Ras癌基因的功能被许多科学家认为是癌症治疗学的“圣杯”,因为这些基因的突变驱动了许多不同类型的癌症的生长。在人类中发现的三种Ras基因--H-Ras,K-Ras和N-Ras - 是第一个与癌症发展相关的新基因,以及由VCU Massey癌症中心研究员Paul Dent博士领导的新研究,已经显示最近批准的乳腺癌药物neratinib可以通过意想不到的过程阻断Ras以及其他几种癌基因的功能。

速递:骨关节炎新药获批!1次注射缓解疼痛超过12周

近日,Flexion Therapeutics宣布,美国FDA已批准其新药Zilretta(triamcinolone acetonide缓释注射悬液)上市,治疗骨关节炎引起的膝盖疼痛。值得一提的是,这也是首款获批的关节内注射的缓释注射液。

JAMA:比二甲双胍更有效果的药物将要出现

根据10月17日发表在《美国医学会杂志》(JournaloftheAmericanMedicalAssociation)上的临床证据显示,添加磺酰脲或二甲双胍治疗胰岛素与血红蛋白A1c(HbA1c)约减少1%有关,而添加磺酰脲类(但非二甲双胍)与更多的低血糖事件有关,效果更明显。